GW Pharmaceuticals — Technical Presentation (June 2014)
12 slides from GW Pharmaceuticals's technical presentation, Jun 17, 2014
Slide 1: Epidiolex Expanded Access INDs Physician Reported Treatment Effect Data
Epidiolex® Expanded Access INDs Physician Reported Treatment Effect Data 17 June 2014 GW Pharmaceuticals
Slide 2: Forward Looking Statements
Forward Looking Statements 2 This presentation contains forward-looking statements. Some of the matters discussed concerning our operations and financial performance include estimates and forward-looking statements within the meaning of the Securities Act and the Exchange Act. These forward-looking
Slide 3: Expanded Access Studies
Expanded Access Studies 3 Expanded access studies are uncontrolled, carried out by individual investigators, and not typically conducted in strict compliance with Good Clinical Practices, all of which can lead to a treatment effect which may differ from that in placebo-controlled trials. Data from t
Slide 4: Introduction: Expanded Access IND Data
Treatment-resistant children and young adults (mean age 10.5 years) Epidiolex added to existing meds. Patients on average 2.7 other AEDs Clinical effect data presented on all 27 patients with 12 week data available: Wide range of treatment-resistant epilepsies Data includes all seizures (convulsive
Slide 5: Responder rates, all patients with 12-week data (n=27)
% of Patients All Patients with 12 Week Data (n=27) Responders - Total Seizures >= 50% Responder >= 70% Responder >= 90% Responder Seizure free at 12 weeks Seizure free data = seizure free at weeks 8-12 Total Seizures = Convulsive and Non-Convulsive 48% 41% 22% 15% (n=13) (n=11) (n=6) (n=4) 5
Slide 6: Response Rates – Total Seizures
% of Patients All Patients with 12 Week Data (n=27) Response Rates – Total Seizures worse 0-24 % decrease 25-49 % decrease 75-100 % decrease 37% 11% 15% 15% 22% 50-74 % decrease (n=10) (n=3) (n=4) (n=4) (n=6) Total Seizures = Convulsive and Non-Convulsive 6
Slide 7: % Reduction in Total Seizure Frequency
% Seizure Reduction mean median 44% 42% All Patients with 12 Week Data (n=27) % Reduction in Total Seizure Frequency FDA efficacy endpoint – average 4 week seizure frequency over 12 weeks vs baseline Total Seizures = Convulsive and Non-Convulsive 7
Slide 8: Dravet Syndrome Responders – Convulsive Seizures
% of Patients >= 50% Responder >= 70% Responder >= 90% Responder Seizure free at 12 weeks Dravet Syndrome Patients (n=9) Responders - Total Convulsive Seizures FDA Assessment of Primary Efficacy in Dravet – Convulsive Seizures Only Seizure free data = seizure free weeks 8-12 56% 44% 33% 33% (n=5) (n
Slide 9: Dravet Syndrome Response Rates – Convulsive Seizures
% of Patients worse 0-24 % decrease 25-49 % decrease 75-100 % decrease 50-74 % decrease 33% 22% 22% 11% 11% Dravet Syndrome Patients (n=9) Response Rates - Convulsive Seizures FDA Assessment of Primary Efficacy in Dravet – Convulsive Seizures Only (n=3) (n=2) (n=2) (n=1) (n=1) 9
Slide 10: Dravet Syndrome % Reduction in Convulsive Seizures
% Seizure Reduction mean median 52% 63% Dravet Syndrome Patients (n=9) % Reduction in Convulsive Seizures FDA efficacy endpoint – average 4 week seizure frequency over 12 weeks vs baseline FDA Assessment of Primary Efficacy in Dravet – Convulsive Seizures Only 10
Slide 11: Safety Data
Safety Data (62 patients, 122 patient months treatment) 81% (50 patients) reported any adverse event, 80% mild or moderate Most common AEs – all causes (10% or more of patients) - Somnolence 40% - Decreased appetite 11% - Fatigue 26% - Increased appetite 10% - Diarrhoea 16% No withdrawals due to AEs
Slide 12: Conclusions
Conclusions Promising signals of efficacy, especially in Dravet syndrome High proportion show >50% reduction in seizure frequency Seizure freedom in a portion of responders 80% of adverse events were mild or moderate; No withdrawals due to adverse events Data support decision to advance Epidiolex in
GW Pharmaceuticals — Technical Presentation (June 2014) on 6ix